// App-Quantinova.ai

5008 : A randomized phase 2 study investigating 3 dosing regimens of radium-223 dichloride (Ra-223) in bone metastatic castration-resistant prostate cancer (mCRPC).

Researchers

Presenter

  • Cora N. Sternberg

Principal Investigators

  • Fred Saad

  • Julie Nicole Graff

  • Avivit Peer

  • Ulka N. Vaishampayan

  • Eugene Leung

  • Eli Rosenbaum

  • Howard Gurney

  • Richard Epstein

  • Ian D. Davis

  • Bingyan Wu

  • Lucia Trandafir

  • Volker Jean Wagner

  • Maha Hussain

Medical Centers

  • San Camillo-Forlanini Hospital, Rome, Italy

  • Centre Hospitalier de LUniversite de Montreal (CHUM), Montreal, QC, Canada

  • Oregon Health and Science University, Portland, OR

  • Rambam Health Care Campus, Haifa, Israel

  • Karmanos Cancer Institute, Detroit, MI

  • The Ottawa Hospital, Ottawa, ON, Canada

  • Rabin Medical Center, Davidoff Center, Petah Tikva, Israel

  • Westmead Hospital, Westmead, Australia

  • The Kinghorn Cancer Centre, St Vincents Hospital, Sydney, Australia

  • Monash University Eastern Health Clinical School, Melbourne, Australia

  • Bayer HealthCare Pharmaceuticals, Whippany, NJ

  • Bayer Consumer Care AG, Basel, Switzerland

  • Division of Hematology/Oncology, Robert H. Lurie Cancer Center Northwestern University Feinberg School of Medicine, Chicago, IL

Locations

  • Canada

  • Italy

  • Switzerland

  • Australia

  • United States

  • Israel

Companies

  • Bayer HealthCare Pha

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Prostate cancer

Biomarkers

  • Exostosin Glycosyltransferase 1

Drug/Treatment

  • Alpharadin

  • Radium-223 Dichloride

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • II

Study Id's

  • NCT02023697

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved